ORIGINAL ARTICLE
Towards standardized categorization of serous effusions: application of the International System for Reporting Serous Fluid Cytopathology diagnostic framework with a special emphasis on borderline ovarian tumors
1
Department of Pathology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
Submission date: 2025-10-11
Final revision date: 2025-11-10
Acceptance date: 2025-11-19
Publication date: 2026-02-23
Corresponding author
Suguna Badiginchala
Dr Suguna Badiginchala, MD, PDCC (Oncopath), DipRCPath Assistant professor, Department of Pathology Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati Andhra Pradesh, India
Dr Suguna Badiginchala, MD, PDCC (Oncopath), DipRCPath Assistant professor, Department of Pathology Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati Andhra Pradesh, India
Pol J Pathol 2025;76(4):329-337
KEYWORDS
TOPICS
ABSTRACT
Borderline ovarian tumors (BOT) in effusion cytology are rare, and to date only limited literature has existed.
The current study used the International System for Reporting Fluid Cytopathology (ISRSFC) criteria to reclassify 321 effusion cytology cases from 302 patients, analyzed diagnostic performance among different positive groups and evaluated the risk of malignancy (ROM). A total of 14 BOTs were included, majority of them were mucinous borderline and these tumors were reclassified into atypia of uncertain significance (AUS) and suspicious for malignancy (SFM) intermediate categories. According to ISRSFC criteria, effusion cases were categorized into five different groups: non-diagnostic (ND), negative for malignancy, AUS, SFM and malignant.
The corresponding overall ROMs were 23.3%, 19.4%, 44%, 87.8% and 100%. Morphologically, mucinous BOTs in effusions presented mostly as acellular mucin, while serous BOTs exhibited mesothelial cells with few atypical cells showing mild to moderate nuclear atypia.
These findings highlight the diagnostic difficulty of BOTs in effusion cytology and the need to apply ISRSFC criteria especially for AUS and SFM grey zone categories for standard reporting and clinical guidance.
The current study used the International System for Reporting Fluid Cytopathology (ISRSFC) criteria to reclassify 321 effusion cytology cases from 302 patients, analyzed diagnostic performance among different positive groups and evaluated the risk of malignancy (ROM). A total of 14 BOTs were included, majority of them were mucinous borderline and these tumors were reclassified into atypia of uncertain significance (AUS) and suspicious for malignancy (SFM) intermediate categories. According to ISRSFC criteria, effusion cases were categorized into five different groups: non-diagnostic (ND), negative for malignancy, AUS, SFM and malignant.
The corresponding overall ROMs were 23.3%, 19.4%, 44%, 87.8% and 100%. Morphologically, mucinous BOTs in effusions presented mostly as acellular mucin, while serous BOTs exhibited mesothelial cells with few atypical cells showing mild to moderate nuclear atypia.
These findings highlight the diagnostic difficulty of BOTs in effusion cytology and the need to apply ISRSFC criteria especially for AUS and SFM grey zone categories for standard reporting and clinical guidance.
REFERENCES (20)
1.
Zamboni MM, da Silva CT Jr., Baretta R, Cunha ET, Cardo- so GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med 2015; 15: 29.
2.
Chandra A, Crothers B, Kurtycz D, Schmitt F. Announcement: the International System for Reporting Serous Fluid Cytopathology. Acta Cytol 2019; 63: 349-351.
3.
Chandra A, Crothers B, Kurtycz D, Schmitt F. The International System for Reporting Serous Fluid Cytopathology. 1st ed. Cham: Springer, Berlin 2020. .
4.
Srinivasan R, Rekhi B, Rajwanshi A, Pathuthara S, Mathur S, Jain D, et al. Indian Academy of Cytologists Guidelines for Collection, Preparation, Interpretation, and Reporting of Serous Effusion Fluid Samples. J Cytol 2020; 37: 1-11.
5.
Kundu R, Srinivasan R, Dey P, Gupta N, Gupta P, Rohilla M, et al. Application of Indian Academy of Cytologists guidelines for reporting serous effusions: an institutional experience. J Cytol 2021; 38: 1-7.
6.
Yang H, Zhu J, Wang P. Application of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) in reporting serous effusion. A retrospective study. Medicine 2023; 102: 43.
7.
Pergaris A, Stefanou D, Keramari P, Sousouris S, Kavantzas N, Gogas H, et al. Application of the International System for Reporting Serous Fluid Cytopathology with Cytohistological Correlation and Risk of Malignancy Assessment. Diagnostics (Basel) 2021; 11: 2223.
8.
Straccia P, Chiappetta M, Magnini D, Cancellieri A. Application of the International System for Reporting Serous Fluid Cytopathology (TIS): a retrospective institutional study. Cytopathology 2022; 33: 305-311.
9.
Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 ml is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases. Cancer Cytopathol 2014; 122: 657-665.
10.
Pinto D, Cruz E, Branco D, Linares C, Carvalho C, Silva A, et al. Cytohistological correlation in pleural effusions based on the International System for Reporting Serous Fluid Cytopathology. Diagnostics (Basel) 2021; 11: 1126.
11.
Lobo C, Costa J, Petronilho S, Monteiro P, Leça L, Schmitt F. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center. Diagn Cytopathol 2021; 49: 596-605.
12.
Rakheja G, Singh M, Priyadarshnee B, Marimuthu B, Dhar L, Jain S, et al. Categorisation of peritoneal serous effusions using the International System for Reporting Serous Fluid Cytopathology – a study on gynaecological samples. Cytopathology 2023; 34: 138-145.
13.
Rajeswaran PK, Srinivasan V, Mahesh SSV, Ashok AU. A retrospective analysis of the application of the newly proposed International System for Reporting Serous Fluid Cytopathology on serous effusion specimens: an institutional experience. Acta Cytologica 2023; 67: 70‑79.
14.
Song MJ, Jo U, Jeong JS, Cho KJ, Gong G, Cho YM, et al. Clinico-cytopathologic analysis of 574 pericardial effusion specimens: application of the international system for reporting serous fluid cytopathology (ISRSFC) and long-term clinical follow-up. Cancer Med 2021; 10: 8899-908.
15.
Wang M, Sun T, Jiao J, Wang H. Application of the International System for Reporting Serous Fluid Cytopathology to pericardial fluid: root-cause analysis of indeterminate diagnoses, cyto-histological correlation, and assessment of risk of malignancy. Cancer Cytopathol 2023; 131: 433-441.
16.
Da Silva DJC, Dos Santos CR, Xavier-Júnior JCC. Risk of Malignancy in Effusions according to the International System for Serous Fluid Cytopathology: a review. Acta Cytol 2024; 68: 384-393.
17.
Zhu YL, Ren WH, Wang Q, Jin HZ, Guo YY, Lin DM. A retrospective analysis of serous effusions based on the newly proposed international system for reporting serous fluid cytopathology: a report of 3633 cases in an oncological center. Diagn Path 2022; 17: 56.
18.
Sharma S, Mohapatra DS, Gupta N, Srinivasan R, Rajwanshi A, Dey P. Cytology of peritoneal implants of borderline serous tumor of ovaries in ascitic fluid. Cytojournal 2021; 18: 17.
19.
Lu CH, Liu CY, Jhuang JY, Chen CC. Comprehensive evaluation of benign and malignant etiologies of different serous effusions with the International System for Reporting Serous Fluid Cytopathology: a multi-institutional study in Taiwan. Cancer Cytopathol 2024; 132: 169-178.
20.
Lim KH, Ahmed SS, Cheng XM, Hwang JSG, Karunanithi J, Mantoo S et al. A single tertiary institution review of the International System for Serous Fluid Cytopathology and the impact of cell block and ancillary studies on its performance. J Am Soc Cytopathol 2023; 12: 48-57.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
